These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. Gros Y; Schuldiner S J Biol Chem; 2010 Feb; 285(7):5076-84. PubMed ID: 20007701 [TBL] [Abstract][Full Text] [Related]
45. Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other? Stahl SM CNS Spectr; 2018 Aug; 23(4):239-247. PubMed ID: 30160230 [TBL] [Abstract][Full Text] [Related]
46. Specific derivatization of the vesicle monoamine transporter with novel carrier-free radioiodinated reserpine and tetrabenazine photoaffinity labels. Sievert MK; Hajipour AR; Ruoho AE Anal Biochem; 2007 Aug; 367(1):68-78. PubMed ID: 17559790 [TBL] [Abstract][Full Text] [Related]
48. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. Eyerman DJ; Yamamoto BK J Neurochem; 2007 Nov; 103(3):1219-27. PubMed ID: 17683483 [TBL] [Abstract][Full Text] [Related]
49. Evaluating depression and suicidality in tetrabenazine users with Huntington disease. Schultz JL; Killoran A; Nopoulos PC; Chabal CC; Moser DJ; Kamholz JA Neurology; 2018 Jul; 91(3):e202-e207. PubMed ID: 29925548 [TBL] [Abstract][Full Text] [Related]
50. HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes. Midde NM; Gomez AM; Zhu J J Neuroimmune Pharmacol; 2012 Sep; 7(3):629-39. PubMed ID: 22570010 [TBL] [Abstract][Full Text] [Related]
51. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Pettibone DJ; Totaro JA; Pflueger AB Eur J Pharmacol; 1984 Jul; 102(3-4):425-30. PubMed ID: 6489435 [TBL] [Abstract][Full Text] [Related]
52. Structural mechanisms for VMAT2 inhibition by tetrabenazine. Dalton MP; Cheng MH; Bahar I; Coleman JA Elife; 2024 Mar; 12():. PubMed ID: 38517752 [TBL] [Abstract][Full Text] [Related]
53. Ketanserin and tetrabenazine abolish aggression in mice lacking monoamine oxidase A. Shih JC; Ridd MJ; Chen K; Meehan WP; Kung MP; Seif I; De Maeyer E Brain Res; 1999 Jul; 835(2):104-12. PubMed ID: 10415365 [TBL] [Abstract][Full Text] [Related]
54. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Chen JJ; Ondo WG; Dashtipour K; Swope DM Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259 [TBL] [Abstract][Full Text] [Related]